Pfizer has agreed to acquire Ferrosan’s consumer healthcare business from Altor 2003 Fund GP.
The Denmark-based pharmaceutical company serves a broad European market including Russia, Ukraine, Poland, and Turkey.
Pfizer Consumer Healthcare president Paul Sturman said, “Ferrosan is an excellent strategic fit that strengthens our presence in dietary supplements with a new set of compelling brands and product pipeline.”
Ferrosan’s portfolio includes multivitamin brand multi-tabs, probiotic Bifiform and the Omega 3 supplement Flyt /Active Omega.
The transaction is subject to customary closing conditions and regulatory approval, but is expected to close during the second quarter of 2011. Financial terms have not been disclosed.